Adjuvant treatment of atopic eczema: Assessment of an emollient containing N-palmitoylethanolamine (ATOPA study)

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 1, 2008, Pages 73-82

  Eberlein, B ^a,b   Eicke, C ^c   Reinhardt, H W ^d   Ring, J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c Stiefel Laboratories ^*

^d Stiefel Laboratories   (Germany)

Author keywords

Atopic eczema; Palmitamide; Palmitoylethanolamine; Skin care; Topical corticosteroids

Indexed keywords

ACETAMIDE; ACYLGLYCEROL; ANTIHISTAMINIC AGENT; BETAINE; CARBOMER; CORTICOSTEROID; EMOLLIENT AGENT; GLYCEROL; HYDROXYETHYLCELLULOSE; IMMUNOMODULATING AGENT; OLIVE OIL; PALM GLYCERIDE; PALMIDROL; PHOSPHATIDYLCHOLINE; PHYSIOGEL; SARCOSINE; SQUALENE; UNCLASSIFIED DRUG; XANTHAN;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; BURNING SENSATION; CHEMICAL COMPOSITION; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CREAM; DATA BASE; DISEASE SEVERITY; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SELF EVALUATION; SKIN CARE; SLEEP; SYMPTOM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ADJUVANTS, PHARMACEUTIC; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; EMOLLIENTS; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PALMITIC ACIDS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 37749016059     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02351.x     Document Type: Article

References (24)

1. Ring J, Przybilla B, Ruzicka T, eds. Handbook of Atopic Eczema, 2nd edn. Springer, Heidelberg, 2005.
2. Ring J. Allergy in Practice. Springer, Berlin, New York, 2005.
3. Rajka G. Essential Aspects of Atopic Dermatitis. Springer, Berlin, Heidelberg, New York, 1989.
4. Bieber T, Leung DYM, eds. Atopic Dermatitis. Marcel Dekker Inc., New York, 2002.
5. Finlay AY. Quality of life in atopic dermatitis. J Am Acad Dermatol 2001; 45 (1 Suppl.): S64-S66.
6. Meuer M, Fartasch M, Albrecht G et al., CASM-DE-01 Study Group. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004; 208: 365-372.
7. Reitamo S, Ortonne JP, Sand C et al., European Tacrolimus Ointment Study Group. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152: 1282-1289.
8. Darsow U, Lübbe J, Taieb A et al., for the European Task Force on Atopic Dermatitis. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005; 19: 286-295.
9. Darsow U, Ring J. Atopic eczema, allergy and the atopy patch test. Allergy Clin Immunol Int 2002; 14: 170-173.
10. Ring J, Brockow K, Abeck D. The concept of patient management in atopic eczema. Allergy 1996; 51: 206-213.
11. Przybilla B, Eberlein-König B, Rueff F. Practical management of atopic eczema. Lancet 1994; 343: 1342-1346.
12. Williams HC. On the definition and epidemiology of atopic dermatitis. Dermatol Clin 1995; 13: 649-657.
13. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermatovener 1980; 92: 44-47.
14. Schnopp C, Holtmann C, Stock S et al. Topical steroids under wet-wrap dressings in atopic dermatitis -a vehicle-controlled trial. Dermatology 2002; 204: 56-59.
15. Brüning H, Knaußmann HG, Rüther TH, Ude R. Ergebnisse einer klinischen Anwendungsbeobachtung bei Patienten mit Neurodermitis. Derm 2002; 8: 355-358.
16. Schlippe G, Ständer M. Anwendung einer Creme mit membranbildenden Lipiden bei Patienten mit atopischer Dermatitis. Haut 2003; 14: 33-35.
17. Ständer S, Schmelz M, Metze D, Luger T, Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 2005; 38: 177-188.
18. Facci L, Toso RD, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 1995; 92: 3376-3380.
19. Rukwied R, Dvorak M, Watkinson A, McGlone F. Putative role of cannabinoids in experimentally induced itch and inflammation in human skin. In: Yosipovitch G, Greaves MW, Fleischer AB Jr, Mc-Glone F, eds. Itch: Basic Mechanisms and Therapy. Marcel Dekker Inc., New York, 2004: 115-130.
20. Di Marzo V, Melck D, Orlando P et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 2001; 358: 249-255.
21. Lo Verme J, Fu J, Astarita G et al. The nuclear receptor peroxisome proliferator-activated receptor mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005; 67: 15-19.
22. Wohlrab J, Herrmann A. Anti-inflammatory lipid components for topical use. J Cosmet Dermatol 2004; 2: 99-104.
23. Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: A preliminary study. Acta Dermatovenerol Croat 2005; 13: 97-103.
24. Kemeny L. Comparison of S236 cream to hydrocortisone 1% cream in the treatment of mild to moderate atopic dermatitis. J Am Acad Dermatol 2005; 52: 68.